Published on Friday February 05, 2016
Smooth initiates a phase II trial in patients with chronic HDVSmooth Drug Development initiates a phase II trial in patients with chronic HDV. The trial will involve 60 patients with chronic HDV which will be enrolled at 12 sites across Russia.
Phase II trials are planned when the drug has demonstrated acceptable safety profile in phase I study. The main objectives of these studies are safety assessment, selection of administration regimens and doses in patiens.
If necessary, we involve our referral network, provide sites with trained personnel, as well as help to obtain approvals and training for newbie sites.